IF-F, IF-IC
M
Endogenous
Rabbit IgG
#Q64735
12946
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Immunofluorescence (Frozen) | 1:50 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
Storage
Specificity / Sensitivity
Species Reactivity:
Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of mouse Crry protein.
Background
Crry, also known as complement component receptor 1-like protein (Cr1l), is a murine membrane-bound complement regulatory protein ubiquitously expressed in mouse tissues (1,2). Crry is a functional analog of the human complement decay-accelerating factor (DAF/CD55) and membrane cofactor protein (MCP/CD46) (3). In mice, Crry acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissues (4,5). Crry also acts as a decay-accelerating factor, preventing the formation of C4b2a and C3bBb, which are amplification convertases of the complement cascade (3,6). Crry plays a crucial role in early embryonic development by maintaining fetomaternal tolerance (7). On CD4+ T cells, Crry acts as a costimulatory factor which favors IL-4 rather than IFN-gamma secretion, suggesting Th2 polarization (8). Cancer cells and cells of the tumor microenvironment have been shown to overexpress Crry, suppressing tumor-specific T cell responses and complement-mediated anti-tumor immunity (9,10). Multiple isoforms have been identified computationally.
- Paul, M.S. et al. (1989) J Immunol 142, 582-9.
- Li, B. et al. (1993) J Immunol 151, 4295-305.
- Foley, S. et al. (1993) Eur J Immunol 23, 1381-4.
- Molina, H. et al. (1992) J Exp Med 175, 121-9.
- Miwa, T. et al. (2002) Blood 99, 3707-16.
- Kim, Y.U. et al. (1995) J Exp Med 181, 151-9.
- Xu, C. et al. (2000) Science 287, 498-501.
- Fernández-Centeno, E. et al. (2000) J Immunol 164, 4533-42.
- Varela, J.C. et al. (2008) Cancer Res 68, 6734-42.
- Ohta, R. et al. (2004) J Immunol 173, 205-13.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
